Adsorbed plasma proteins and cellular integrins

The interaction between adsorbed plasma proteins and cellular integrins constitutes the primary biological response to implanted medical devices and biomaterials. Upon contact with blood or interstitial fluid, proteins such as fibrinogen, fibronectin, and vitronectin rapidly coat the material surface, often undergoing conformational changes that expose cryptic binding sites (Wilson et al., 2005). These sites are then recognized by integrin receptors on the surface of circulating cells, most notably αIIbβ3 on platelets and Mac-1 (αMβ2) on leukocytes (Hu et al., 2001). This molecular recognition triggers a cascade of events including platelet activation, leukocyte activation, and the release of inflammatory cytokines. This process, known as the foreign body response, can lead to clinical complications such as thrombosis, chronic inflammation, and the formation of a dense fibrous capsule that may impair device function (Anderson et al., 2008). Therapeutic interventions target this interface through the use of anti-integrin drugs like Abciximab or by modifying the biomaterial surface to be protein-resistant using coatings like polyethylene glycol (Lutolf & Hubbell, 2005). Managing this interaction is essential for the long-term success of cardiovascular stents, orthopedic implants, and biosensors.

Other names

Protein-material interfaceIntegrin-ligand complexForeign body response interfaceVroman effect interface

Inhibition of integrin-ligand binding to prevent platelet aggregation or leukocyte activation; modification of surface chemistry to prevent protein adsorption.